Zhiyu Pan

Dr. Zhiyu Pan

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2023 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
SMsijia ma
sijia ma
BYBin Yang
Bin Yang
MZMingming Zhao
Mingming Zhao
PLPeng Li
Peng Li
JFJiao Fan
Jiao Fan
YZYu Zhang
Yu Zhang

22 February 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
MZMingming Zhao
Mingming Zhao
ZZZiyan Zhang
Ziyan Zhang
ZPZhiyu Pan
Zhiyu Pan
SMsijia ma
sijia ma
MCMeiying Chang
Meiying Chang
YZYu Zhang
Yu Zhang
Renin-angiotensin system (RAS) inhibitors and calcium channel blockers (CCB) are often used together in chronic kidney disease (CKD). The PubMed, EMBASE, and Cochrane Library databases were searched to identify randomized controlled trials (RCTs) in order to explore better subtypes of CCB for the treatment of CKD. This meta-analysis of 12 RCTs with 967 CKD patients who were treated with RAS inhibitors demonstrated that, when compared with L-type CCB, N-/T-type CCB was superior in reducing urine albumin/protein excretion (SMD, −0.41; 95% CI, −0.64 to −0.18; p < 0.001) and aldosterone, without influencing serum creatinine (WMD, −3.64; 95% CI, −11.63 to 4.35; p = 0.37), glomerular filtration rate (SMD, 0.06; 95% CI, −0.13 to 0.25; p = 0.53), and adverse effects (RR, 0.95; 95% CI, 0.35 to 2.58; p = 0.93). In addition, N-/T-type CCB did not decrease the systolic blood pressure (BP) (WMD, 0.17; 95% CI, −1.05 to 1.39; p = 0.79) or diastolic BP (WMD, 0.64; 95% CI, −0.55 to 1.83; p = 0.29) when compared with L-type CCB. In CKD patients treated with RAS inhibitors, N-/T-type CCB is more effective than L-type CCB in reducing urine albumin/protein excretion without increased serum creatinine, decreased glomerular filtration rate, and increased adverse effects. The additional benefit is independent of BP and may be associated with decreased aldosterone (PROSPERO, CRD42020197560).

10 March 2023 in Medicine
Verified
Journal Article
Open access
ZPZhiyu Pan
Zhiyu Pan
MZMingming Zhao
Mingming Zhao
MCMeiying Chang
Meiying Chang
XSXiujie Shi
Xiujie Shi
SMSijia Ma
Sijia Ma
YZYu Zhang
Yu Zhang
Background: IgA nephropathy (IgAN) is a common primary glomerular disease, and supplementing qi dispelling wind and activating blood is commonly used as a treatment method in Chinese medicine. However, the existing studies have small sample sizes. This study aimed to use a meta-analysis to explore the clinical efficacy of this method and to systematically introduce this effective treatment. Methods: We searched for randomized controlled trial studies on supplementing qi dispelling wind and activating blood circulation methods for IgAN indexed in the China National Knowledge Infrastructure, Wanfang Data, Chongqing VIP, SinoMed, PubMed, EMBASE, and Web of Science databases, which were interrogated from database inception to January 2022. Combining the inclusion and exclusion criteria to screen the literature, we included a total of 15 eligible studies; the quality of the included studies was evaluated using the risk of bias assessment tool of the Cochrane System Revies Manual 5.4. The outcome indexes were extracted, and a meta-analysis was performed using Review Manager 5.4 software. Results: Fifteen articles were included in this review. A meta-analysis of the results led to the conclusion that supplementing qi dispelling wind and activating blood circulation prescription has beneficial effects on the total effective rate [odds ratios = 3.95, 95% confidence interval (CI) 2.76–5.67], and can reduce 24-hour urinary protein quantity (mean deviation = −0.35, 95% CI −0.54 to −0.16) and serum creatinine (mean deviation = −15.41,95% CI −28.39 to −2.44) without impact normal level of alanine transaminase, hemoglobin, and serum albumin. Conclusions: Supplementing qi dispelling wind and activating blood can significantly improve renal function and reduce 24-hour urinary protein quantity levels in patients with IgAN compared to the use of non-Chinese medicine treatment. This finding provides a rationale for using this method in the clinical treatment of IgAN.